BioDtech, Inc. (BDTI) an emerging life science company, today announced the release of EndoPrep™, the first product designed for the safety of genetically engineered and protein drugs. EndoPrep™ allows for the more accurate detection of a toxin associated with the production of antibodies, recombinant proteins and synthetic peptides which are the basis for new cancer, cardiovascular, neurological, infectious and metabolic diseases. The toxin is masked by these drugs in the current FDA approved methods for detection. EndoPrep™ removes the drug allowing the toxin to be exposed and detected by standard assays.

“This unique product can be used with other standard assays for hormones, drugs, pollutants and extraction of DNA for PCR analysis. Additionally, no hazardous reagents are used-no organic solvents or detergents for extraction,” commented Michael Pepe, President and CEO of BDTI.

The company has a growing product line and licensing options are available by contacting businessdevelopment@biodtechinc.com. BDTI is located in the Innovation Depot in downtown Birmingham, AL. Innovation Depot is a joint partnership with the University of Alabama at Birmingham (UAB).

BioDtech, Inc. will also be presenting at BioNetwork East in Naples, Florida March 16-18, 2009.